PAGANINI, CLAUDIA
 Distribuzione geografica
Continente #
AS - Asia 71
NA - Nord America 59
EU - Europa 40
Totale 170
Nazione #
US - Stati Uniti d'America 57
SG - Singapore 34
HK - Hong Kong 27
DE - Germania 10
IT - Italia 9
ID - Indonesia 7
FI - Finlandia 6
RU - Federazione Russa 5
PL - Polonia 3
NL - Olanda 2
PH - Filippine 2
PT - Portogallo 2
AT - Austria 1
CA - Canada 1
ES - Italia 1
GB - Regno Unito 1
JO - Giordania 1
PA - Panama 1
Totale 170
Città #
Singapore 30
Hong Kong 27
Council Bluffs 7
Jakarta 7
Munich 7
Engelhard 4
Santa Clara 4
Espoo 3
Los Angeles 3
Rome 3
Warsaw 3
Del Norte 2
Frankfurt am Main 2
Helsinki 2
Manila 2
Porto 2
Senigallia 2
Turin 2
Amman 1
Ashburn 1
Billings 1
Lappeenranta 1
London 1
Moscow 1
New Hampton 1
Nuremberg 1
Ottawa 1
Recanati 1
Salt Lake City 1
San Jose 1
St. George 1
Valencia 1
Totale 126
Nome #
Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks 35
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab 28
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema: A Retrospective Study 28
Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks 22
letter in response to the case report: “recalcitrant generalized granuloma annulare treated successfully with dupilumab” 21
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice 15
Characterization of Super-Responder Profile in Chronic Plaque Psoriatic Patients under Guselkumab Treatment: A Long-Term Real-Life Experience 13
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis 13
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View 13
Long-Term Persistence Rate of Secukinumab in Psoriatic Patients: A Six-Year Multicenter, Real-World Experience, Retrospective Study 13
Eczematous liraglutide eruption managed by dupilumab: A case report 10
Comment on “A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council”- A case of Rhabdomyolysis Induced by Upadacitinib 1
Totale 212
Categoria #
all - tutte 1.274
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.274


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202444 0 0 0 0 0 0 4 5 0 16 18 1
2024/2025168 5 27 16 55 16 44 5 0 0 0 0 0
Totale 212